Natural Product (NP) Details
| General Information of the NP (ID: NP0074) | |||||
|---|---|---|---|---|---|
| Name |
Acteoside
|
||||
| Synonyms |
Acteoside; Verbascoside; 61276-17-3; Kusaginin; acetoside; Verbacoside; TJC 160; UNII-3TGX09BD5B; NSC 603831; 3TGX09BD5B; [(2R,3R,4R,5R,6R)-6-[2-(3,4-dihydroxyphenyl)ethoxy]-5-hydroxy-2-(hydroxymethyl)-4-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl] (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate; [(2R,3R,4R,5R,6R)-6-[2-(3,4-dihydroxyphenyl)ethoxy]-5-hydroxy-2-(hydroxymethyl)-4-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyl-tetrahydropyran-2-yl]oxy-tetrahydropyran-3-yl] (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate; beta-D-Glucopyranoside, 2-(3,4-dihydroxyphenyl)ethyl 3-O-(6-deoxy-alpha-L-mannopyranosyl)-, 4-[(2E)-3-(3,4-dihydroxyphenyl)-2-propenoate]; Verbacoside;; Acteoside;; MFCD00221751; MLS002473233; SCHEMBL657970; CHEBI:9953; CHEMBL231853; CHEMBL444478; cid_5281800; Verbascoside, >=99% (HPLC); CHEBI:132853; cid_24978601; HMS2205K11; 22323-52-0; HY-N0021; ZINC8234351; BDBM50241867; s5458; AKOS015897165; CCG-270269; DB12996; AS-75167; Glucopyranoside, 2-(3,4-dihydroxyphenyl)ethyl 3-O-(6-deoxy-alpha-L-mannopyranosyl)-, 4-(3-(3,4-dihydroxyphenyl)-2-propenoate), (E)-beta-D-; SMR001397320; N1341; V1534; C10501; 276A173; B864379; Q411426; Q-100706; Verbascoside, primary pharmaceutical reference standard; UNII-3TGX09BD5B component FBSKJMQYURKNSU-ZLSOWSIRSA-N; Verbascoside, United States Pharmacopeia (USP) Reference Standard; ((2R,3R,4R,5R,6R)-6-(3,4-dihydroxyphenethoxy)-5-hydroxy-2-(hydroxymethyl)-4-((2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yloxy)tetrahydro-2H-pyran-3-yl) 3-(3,4-dihydroxyphenyl)acrylate; ((2R,3R,4R,5R,6R)-6-(3,4-dihydroxyphenethoxy)-5-hydroxy-2-(hydroxymethyl)-4-((2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yloxy)tetrahydro-2H-pyran-3-yl)3-(3,4-dihydroxyphenyl)acrylate; (2R,3R,4R,5R,6R)-6-[2-(3,4-dihydroxyphenyl)ethoxy]-5-hydroxy-2-(hydroxymethyl)-4-{[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-3-yl (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoate; (3,4-Dihydroxyphenyl)ethyl O-.alpha.-rhamnopyranosyl(1->3)-4-O-caffeoyl-.beta.-D glucopyranoside; .beta.-D-Glucopyranoside, 2-(3,4-dihydroxyphenyl)ethyl 3-O-(6-deoxy-.alpha.-L-mannopyranosyl)-, 4-[(2E)-3-(3,4-dihydroxyphenyl)-2-propenoate]; .beta.-D-Glucopyranoside, 2-(3,4-dihydroxyphenyl)ethyl3-O-(6-deoxy-.alpha.-L-mannopyranosyl)-, 4-[(2E)-3-(3,4-dihydroxyphenyl)-2-propenoate]; 2-(3,4-dihydroxyphenyl)ethyl 3-O-(6-deoxy-alpha-L-mannopyranosyl)-4-O-[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]-beta-D-glucopyranoside; 2-(3,4-dihydroxyphenyl)ethyl 3-O-(alpha-L-rhamnopyranosyl)-4-O-[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]-beta-D-glucopyranoside; 3,4-Dihydroxyphenethyl 3-O-alpha-L-rhamnopyranosyl-4-O-[3-(3,4-dihydroxyphenyl)acryloyl]-beta-D-glucopyranoside
Click to Show/Hide
|
||||
| Species Origin | Cistanche ... | Click to Show/Hide | |||
| Cistanche | |||||
| Disease | Nephritic syndrome [ICD-11: GB40] | Terminated | [1] | ||
| Structure |
|
Click to Download Mol2D MOL |
|||
| ADMET Property |
Absporption
Caco-2 Permeability
-6.594
MDCK Permeability
-5.194
PAMPA
+++
HIA
+++
Distribution
VDss
-0.328
PPB
65%
BBB
- - -
Metabolism
CYP1A2 inhibitor
- - -
CYP1A2 substrate
- - -
CYP2C19 inhibitor
- - -
CYP2C19 substrate
- - -
CYP2C9 inhibitor
- - -
CYP2C9 substrate
- - -
CYP2D6 inhibitor
- - -
CYP2D6 substrate
- - -
CYP3A4 inhibitor
- - -
CYP3A4 substrate
- - -
CYP2B6 inhibitor
+++
CYP2B6 substrate
- - -
CYP2C8 inhibitor
+++
HLM Stability
+++
Excretion
CLplasma
3.177
T1/2
4.313
Toxicity
DILI
++
Rat Oral Acute Toxicity
- - -
FDAMDD
- - -
Respiratory
- - -
Human Hepatotoxicity
-
Ototoxicity
+++
Drug-induced Nephrotoxicity
-
Drug-induced Neurotoxicity
- - -
Hematotoxicity
- - -
Genotoxicity
++
Tips: 1. For the classification endpoints, the prediction probability values are transformed into six symbols: 0-0.1 (- - -), 0.1-0.3 (- -), 0.3-0.5 (-), 0.5-0.7 (+), 0.7-0.9 (++), and 0.9-1.0 (+++).
2. Additionally, the corresponding relationships of the three labels are as follows: excellent; medium; poor.
Click to Show/Hide
|
||||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
| Formula |
C29H36O15
|
||||
| PubChem CID | |||||
| Canonical SMILES |
CC1C(C(C(C(O1)OC2C(C(OC(C2OC(=O)C=CC3=CC(=C(C=C3)O)O)CO)OCCC4=CC(=C(C=C4)O)O)O)O)O)O
|
||||
| InChI |
1S/C29H36O15/c1-13-22(36)23(37)24(38)29(41-13)44-27-25(39)28(40-9-8-15-3-6-17(32)19(34)11-15)42-20(12-30)26(27)43-21(35)7-4-14-2-5-16(31)18(33)10-14/h2-7,10-11,13,20,22-34,36-39H,8-9,12H2,1H3/b7-4+/t13-,20+,22-,23+,24+,25+,26+,27+,28+,29-/m0/s1
|
||||
| InChIKey |
FBSKJMQYURKNSU-ZLSOWSIRSA-N
|
||||
| CAS Number |
CAS 61276-17-3
|
||||
| ChEBI ID | |||||
| Herb ID | |||||
| SymMap ID | |||||
| TCMSP ID | |||||
| TTD Drug ID | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
| Gentamicin | Bacterial infection | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| In-vitro Model | Staphylococcus aureus | Microorganism model | Staphylococcus aureus | |||
| Escherichia coli | Microorganism model | Escherichia coli | ||||
| Experimental
Result(s) |
The co-administration of verbascoside and gentamicin was more effective and synergistic activities (FICI<1) against clinical isolates. | |||||
| β. A List of Drug(s) Whose Adverse Effect can be Decreased by This NP | ||||||
| Thymic stromal lymphopoietin | Colon cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [3] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | IL1B | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | IL6 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MDM2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | TNF | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | HMC-1 | CVCL_0003 | Mast cell leukemia | Homo sapiens | ||
| Experimental
Result(s) |
Acteoside is a specific regulator of MDM2 activation in TSLP-stimulated mast cells, which indicates its potential use for the treatment of mast cell-mediated inflammatory diseases. | |||||
| Dextran sulfate sodium | Human immunodeficiency virus disease | Click to Show/Hide the Molecular Data of This Drug | ||||
| Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [4] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | CSF2 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | IFNG | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | IL10 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | TNF | Molecule Info |
Pathway MAP
|
||
| In-vivo Model | Female Balb/c mice weighing 20-22 g were used in this study. | |||||
| Experimental
Result(s) |
In vivo treatment with the herbal phenylethanoid acteoside ameliorates intestinal inflammation in dextran sulphate sodium-induced colitis. | |||||
| X-ray irradiation | Scaphoid Fracture | Click to Show/Hide the Molecular Data of This Drug | ||||
| Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [5] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | Human skin fibroblasts | Healthy | Homo sapiens | |||
| Experimental
Result(s) |
Acteoside could protect the cells from X ray induced damage through enhancing the scavenging activity of ROS, decreasing the Bax/Bcl 2 ratio and downregulating the activity of procaspase 3, as well as modulating the mitogen activated protein kinase signaling pathways. | |||||
| Scopolamine | Addictive disorder | Click to Show/Hide the Molecular Data of This Drug | ||||
| Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [6] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| In-vivo Model | Male ICR mice, weighing 25-30 g, were used for passive avoidance and water maze tests. | |||||
| Experimental
Result(s) |
Acteoside of Callicarpa dichotoma attenuates scopolamine-induced memory impairments. | |||||
| γ. A List of Drug(s) Whose Resistance can be Reversed by This NP | ||||||
| Temozolomide | Brain cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [7] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CD107a | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Phosphorylation | JNK1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | MAP1LC3A | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Phosphorylation | p38 beta | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | C6 | CVCL_0194 | Rat malignant glioma | Rattus norvegicus | ||
| Experimental
Result(s) |
Acteoside has beneficial effects on TMZ based glioblastoma therapy. | |||||